Picture loading failed.

Anti-KLRC1 therapeutic antibody (Pre-made Monalizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Monalizumab (formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies and other cancers.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-355-1mg 1mg 3090
GMP-Bios-ab-355-10mg 10mg 21890
GMP-Bios-ab-355-100mg 100mg 148000
GMP-Bios-ab-355-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-KLRC1 therapeutic antibody (Pre-made Monalizumab biosimilar,Whole mAb)
INN Name Monalizumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesInnate Pharma;MedImmune;NCIC Clinical Trials Group;Novo Nordisk
Conditions Approvedna
Conditions ActiveHead and neck cancer;Non-small cell lung cancer;Cervical cancer;Chronic lymphocytic leukaemia;Endometrial cancer;Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Solid tumours;Haematological malignancies
Conditions DiscontinuedInflammation;Rheumatoid arthritis
Development Techna